Objectives In the current pressured economic context, and to continue to treat the growing number of patients with high-quality standards, the first step is to have a better understanding of the costs related to end-stage renal disease (ESRD) treatment according to various renal replacement therapy, age, diabetes status, and clinical events. Methods In order to estimate the direct costs of all adult ESRD patients, according to (RRT) modality, patient condition, and clinical events, data from the French national health insurance funds were used. Results The mean monthly costs for the 47,862 stable prevalent patients (73 % of the population) varied substantially according to treatment modality (from 7300€ for in-center hemodialysis to 1100€ for a functioning renal graft) and to clinical event (8300€ for the first month of dialysis, 11,000€ for the last month before death, 22,800€ for the first month after renal transplantation). Mean monthly costs varied according to diabetic status and to age to a lesser extent.
Introduction
End-stage renal disease (ESRD) is a major challenge for health care systems around the world because of the growing proportion of the population affected and the ensuing rise in health care costs [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Chronic kidney disease was the 19th cause of global years of life lost in 2013 worldwide [11] . In France, ESRD affected 79,335 patients in 2014 (50 % have more than 64, and 25 % more than 75), with a 3 % growth per year. The cost of care for these patients was high, and was estimated at 4 billion euros in 2007, 3 % of the total budget of the health insurance funds, 0.14 % of the gross domestic product, spent on 1 % of the general population [12] .
Health care systems must attempt to provide appropriate, high-quality, and economically sustainable care that meets the needs and the desires of patients with end-stage renal disease (ESRD).
France offers two modalities of transplantation (from living or deceased donor) and eight different modalities, each characterized by the technique of dialysis, the extent of professional assistance, and the treatment site: hospitalbased in-center HD, HD in medical satellite facilities, HD in self-care units, home HD, nurse-assisted automated PD (APD), non-assisted APD, nurse-assisted continuous ambulatory PD (CAPD), and non-assisted CAPD. Regardless of the environment of the dialysis unit (hospital-based, satellite facilities, self-care units, home dialysis) or the type of provider (university, public, private not for profit, private for profit), each dialysis facility is required to provide medical services 24 h/24 h, and to have back-up available at an in-center dialysis unit. For French policy-makers, the challenge is to be able to continue to treat the growing number of patients with highquality care in the current economic context in order to provide the most efficient care to each patient. They need to have an accurate understanding of the cost of care for patients with ESRD knowing that this cost varies according to specific renal replacement therapy (RRT) modality, patient condition, and clinical events (dialysis start, renal transplantation, death).
In this case, a global estimation is not sufficient and to identify the components of cost of treatment is essential with a view to public decision-making: for example, to analyze the economic impact of change of strategy of care, to make cost-effectiveness studies, to develop a new strategy of treatment, and then to improve the efficiency of this pathology. Most studies have estimated the cost of ESRD patients from the perspective of the health care system. These studies have examined different types of costs: some include only the cost of renal replacement therapy (RRT) [13, 14] , while others consider the global cost of patient care, including for comorbidities [4, 15, 16] . However, in many studies, the cost parameters are not well defined, so comparisons are difficult [17] [18] [19] [20] [21] . Some consider only two or three treatments-peritoneal dialysis (PD), hemodialysis (HD), and transplantation [4, 17, 20, [22] [23] [24] [25] [26] -without any details about treatment site or medical environment (in-center, satellite unit, self-care unit, home) or technique (e.g., automated PD or continuous ambulatory PD, living or deceased graft donor). Some studies compare various specific modalities or techniques [4, 14, 18, 21, [27] [28] [29] [30] [31] [32] .
In all cases, these studies do not take into account the very different characteristics of patients treated according to different modalities, although some characteristics, such as age or diabetes status, may well explain part of the variability of their treatment costs [33] . These potential indication biases are generally not taken into account, and heterogeneous groups are thus compared (e.g., PD, outcenter HD, and transplanted patients are often younger and healthier than HD in-center patients).
Furthermore, these studies provide information about the overall annual costs for ESRD patients but provide few details about the additional transition costs when patients change treatment modalities or states (such as dialysis start [34] , death, or renal transplantation [4, 35] ).
Therefore, due to the lack of information about an accurate estimation of the cost of care for patients with renal replacement therapy for ESRD, we developed a study to estimate, for the first time in France, the costs by ESRD patient according to the all ten RRT modalities and to determine the variability of those costs according to patient condition and clinical events in the health care system perspective, by an analysis based on an exhaustive nationwide database. The aim of this study is to compare the cost of various therapeutic strategies for various characteristics of patients. Our study is a descriptive study and doesn't aim to evaluate the consequences of a health intervention in terms of outcome or to improve cost measurements.
Materials and method

Data used
This retrospective study on reimbursements for ESRD patients used two national exhaustive medico-administrative databases. The French national health insurance information system [36] (SNIIRAM) contains exhaustive ambulatory health care consumption of beneficiaries and associated reimbursed expenditures; The French national hospital computerized medical information system (PMSI) contains exhaustive hospital stays, without cost data. To estimate the cost of hospital care, we used the costs estimated by ATIH (agency which leads PMSI) based on the public health care tariff calculations.
For chronic diseases such as ESRD, all expenses eligible for reimbursement are paid by health insurance; there are no out-of-pocket expenses for patients. Therefore, the data used in our study of ESRD patients permit to estimate the cost of total reimbursable direct resources used.
In the health care system perspective, all direct medical costs were taken into account. In the SNIIRAM and PMSI databases, the following direct medical costs for a patient with ESRD were identified: hospital care, outpatient care (medical, paramedical, and imaging procedures), fees (doctor, nurse, and other health auxiliaries), medical goods (drugs and medical devices), laboratory tests, transportation, and personal autonomy allowances (special allocations for ESRD patients using unassisted dialysis modalities). The identified costs were aggregated data by patient and costs headings.
Population
We identified all adult ESRD patients with treatment paid for by the French national health insurance system during the period from March 1, 2009 , to February 28, 2010 . Dialysis patients were identified by billing for at least one session of dialysis or hospitalization including dialysis for chronic kidney disease. Transplant patients were identified by a chronic kidney disease diagnosis and hospitalization for newly transplanted patients during the period of the study or use of at least three immunosuppressive treatments for patients transplanted before the study period. Patients with acute renal failure or younger than 18 years were excluded. Patients for whom health care reimbursement data or clinical characteristics were unavailable or incomplete were also excluded, resulting in a sample of 65,662 patients ([90 % of the expected total population with ESRD [37] ).
The population was stratified by age (18-44 years, 45-69 years, and 70 years and over) and diabetes status (identified in the database by their consumption of specific antidiabetic drugs).
Classification of the patients according to treatment modality
We took into account all the possible RRT modalities according to the treatment site or medical environment (incenter, satellite unit, self-care unit, home) or technique (automated PD or continuous ambulatory PD, living or deceased graft donor). Ten treatment modalities were defined: nurse-assisted automated peritoneal dialysis (APD), non-assisted APD, nurse-assisted continuous ambulatory peritoneal dialysis (CAPD), non-assisted CAPD, hemodialysis in a hospital-based in-center unit, hemodialysis in a medical out-center satellite unit, hemodialysis in a self-care or nurse-assisted satellite unit, hemodialysis at home, living with renal graft. Because the type of donor could not be distinguished in the health insurance database, renal graft patients were combined into a single group.
Patients can also temporarily be in a training unit for HD in a self-care unit or at home or for non-assisted PD at home.
Patients could move from a treatment modality to another during the study period. In order to estimate the cost by patient for each treatment modality, the trajectory of patients through these ten different modalities during the study period was reconstructed and the time spent in each modality estimated. Patients with the same modality of treatment for at least 75 % of their total treatment time (around 9 months with the same modality) were considered stable in a single modality over the study period, and those who did not (several modalities during 9 months) were considered to have a mixed treatment, with more than one modality.
For mixed treatment, combinations mixing different HD modalities, different PD modalities, or mixing HD and PD with or without graft were considered.
The newly transplanted patients during the study period were also considered separately, whereas patients who were transplanted before the study period and had medications for renal grafts over the study period were considered in the stable or mixed treatment groups.
Estimation of mean monthly costs and transition costs
In order to estimate a mean cost for an ESRD patient and additional costs due to transitions (treatment beginning, death), stable and mixed patients were then classified in subgroups (prevalent, incident, deceased). The subgroups were defined by the occurrence of clinical events.
Patients were considered prevalent if they did not start a new modality of RRT or die or receive a renal transplant during the period. These patients began a RRT before the study period and finished after the study period. The stable prevalent patient subgroup was used to estimate the mean monthly cost for an ESRD patient by treatment modality, and taking into account patient profiles with age and diabetes status. Prevalent patients considered stable in training modality were excluded because supposed to be errors as patients in training during 9 months could not be considered as stable. The mean monthly cost of the mixed prevalent patient subgroup was also estimated for each combination of treatment modalities (HD modalities, PD modalities, mixing HD and PD, with or without graft).
For new patients (incident) who started RRT during the period (pre-emptive renal grafts excluded), the initial cost was based on the first month of treatment, by age and diabetes status. Due to the small size of this incident population, patients were eventually pooled into two groups of treatment modalities: HD or PD. Only the cost of the first month of treatment for incident population was estimated.
For patients who died during the period (incident or prevalent deceased patients), the mean cost of the last month of treatment for each modality was estimated because an additional cost was expected during this last month.
For the patients who received a renal graft during the period (newly transplanted), the monthly cost post-transplant was estimated. This estimate considered the time from transplantation to 6 months, for each age and diabetes status group.
Organ transplantation requires a set of preliminary steps, which include the search for a compatible donor, the organ removal, and the coordination of the entire pretransplant process. Based on the data reported by the national agency for transplantation (Agence de la biomedicine) [36] , we determined-for a kidney transplant-the total cost for all the stages before the actual transplantation act, distinguishing the costs for living and deceased donors. For deceased donors, the following steps are included: the global coordination of organ retrieval, intensive care of potential donors, organ retrieval and all laboratory testing, transportation for the medical teams and the graft, HLA typing of recipients on the waiting list and final crossmatch. Because potential donors may be withdrawn at each step, the estimation is based on 1.2 potential donors for each renal graft. For living donors, the coordination, their medical and laboratory assessment, organ retrieval, and long-term follow-up (38 years: median survival of living donors) were considered.
Analysis
The monthly mean cost of a patient with ESRD was estimated by dividing the total amount spent for each patient during the period by their total participating time. Costs are expressed as mean ± standard deviations and quartiles when specified. In case of small sizes in a particular group, we estimated the monthly cost based on the results of other groups by taking into consideration the differences observed for other modalities. No actualization was applied since our analysis was based on reimbursed data observed in a year.
Results
The mean age of the 65,662 patients included was 61 years, and 23 % of them had diabetes (Table 1) .
Over the study period, 89 % of the total population (58,646 patients) was considered stable, that is, in a single treatment modality for at least 75 % of the study period (Fig. 1) . Fifty-seven percent of these stable patients were treated by hemodialysis (HD), 39 % had a renal graft, and only 4 % were treated by peritoneal dialysis (PD) ( Table 2) . Most of stable patients were prevalent patients alive at the end of the period (47,961 patients, 82 % of the stable population).
Seven percent of the total population has a mixed treatment and 4 % was newly transplanted patients during the study period. Among stable patients, 99 prevalent patients classified stable in HD or PD training units were excluded from the analysis, decreasing the number of prevalent and alive patients to 47,862 over the study period. The mean monthly costs varied substantially according to treatment modality (Fig. 2) .
The analysis by cost headings showed that the major expenses varied according to type of dialysis procedure (Table 3) . In HD modalities, transportation accounted for 17-20 % of the total mean cost, and in assisted PD, the nurses' fees for 26-37 %. Patients using non-nurse-assisted PD received personal autonomy allowances of about 290€ each month (8 % of the total mean cost). For patients with a functioning graft (all donors), 55 % of the costs went to pharmaceutical expenditures. Mean monthly costs also varied according to patient age and diabetes status (Table 4) . Mean costs fluctuated with age, but to a lesser extent than they did with diabetes status.
During the study period, 7133 incident stable patients started RRT. Among them, 91 % were treated by hemodialysis (HD) and 9 % by PD. The mean cost of the first month of treatment was 8258€ (SD 8717€), and it varied according to age, diabetes status, and treatment technique (Table 5 ). Monthly costs were stable during time after the first month and closed to monthly cost estimated in prevalent patients.
During the study period, 4079 (incident and prevalent) patients with stable treatment died. Their mean age was 73 years, and 35 % had diabetes. The mean cost of the last month of treatment was 11,045 € (SD 11,244€). This cost was highest for younger patients (Suppl Table 1 ). The cost of this last month is roughly twice the cost of a month for a stable prevalent patient. Hospitalizations, other than for RRT, accounted for 70 % of the total cost of the last month of treatment.
Among mixed patients, 3248 patients were considered prevalent over the study period: 72 % had various HD modalities, 3 % various PD modalities, and 7 % a combination of the two. The average monthly cost of these mixed prevalent groups were 5940 € (SD 1961€), 4756€ (SD 1583€), and 6637€ (SD 2205€), respectively. The remaining 18 % of prevalent patients had various combinations of dialysis and transplantation.
Renal transplants took place for 2265 patients during the study period. As expected, the mean monthly cost decreased with time ( Table 6 ). The mean cost of the month of transplantation was 22,843€ (SD 10,018€) for 241 patients with pre-emptive transplants and 26,155€ (SD 10,775€) for the others. During the first month after the Pre-emptive graft N=241
Transplantation after dialysis N=2 024
ESRD patients N=65 662
In training (excluded) N=99 A comprehensive approach to assess the costs of renal replacement therapy for end-stage… 463 transplantation, hospitalization accounted for 27 % of the costs. With time, pharmacological expenses became the main item of expenditure. Up to 6 months after transplantation, mean monthly costs increased with age, especially for patients with diabetes. However, at the 6-month point, they continued to increase with age for patients with diabetes, but remained relatively stable for patients without diabetes, regardless of age.
Fig. 1 Flow chart of the ESRD patients' repartition
The costs invoiced in addition to transplantation varied from 19,618€ for a graft from deceased donors to 12,241€ for living donors (Table 7 ) [38] . For deceased donors, 42 % of the cost was related to donor coordination, 26 % to organ retrieval, and 27 % to recipient coordination and HLA typing on the waiting list. In living donors, 35 % of the cost was related to organ retrieval, 37 % to living donor coordination, and 27 % to living donor follow-up.
Discussion
This study, based on the exhaustive nationwide administrative databases of the French national health insurance information system and 2009 public health care tariff calculations, confirms that mean costs varied between each of the ten treatment modalities proposed to ESRD patients in France. The most expensive treatment modality was HD in a hospital-based in-center unit (7253€ monthly per patient) followed by nurse-assisted PD (5744€ for APD-5337€ for CAPD) and HD in medical out-center unit (5196€). The least expensive was renal transplantation (all kinds of donors) with a mean monthly cost of 1128€ per patient. The cost of care varied also with each of two important patient characteristics-age and diabetes status: patients with diabetes, and particularly young patients, had higher mean monthly costs. Moreover, to evaluate the global cost of ESRD patients, clinical events (e.g., dialysis start, renal transplantation, death) and additional costs due to transition between modalities must be considered because they increased the costs of care.
This study provides interesting information to policymakers when discussing various strategies of treatment and their impact in terms of global costs. It advocates a more differentiated approach, taking into account different factors affecting the costs. Especially in the context of aging of the ESRD population and the high frequency of diabetes, future trends and anticipation of health organization and financial needs have to be based on precise data. Those results can be used to develop a cost-effectiveness evaluation of different strategies of renal care in a simulation model [39, 40] .
A previous study [24] based on the reimbursement from the French general health insurance has only considered three treatment modalities (where we considered ten modalities), didn't stratified on patients' characteristics like age and diabetes and didn't take into account the costs of transition between modalities and the additional costs due to dialysis start, renal transplantation or death. Therefore this study, and other European studies of this kind are not fairly accurate to describe in detail all the costs associated with the patients treated for ESRD and the factors associated to the variation of those costs. The results of these It is difficult to compare in more detail our results with those of other studies, because different countries organize their health care and specifically their renal care The mean cost for nurse-assisted PD for 18-44 was estimated compared to non-assisted PD by applying the difference in mean cost between nurse-assisted PD and non-assisted PD in ?45 years patients
The mean cost for HD at home in diabetics was estimated compared to HD in self care unit by applying the difference in mean cost between HD at home and HD in self care unit in non-diabetics * Due to small size (\10), the monthly cost was estimated using these rules differently, fund them differently, and offer different choices of treatment modality and overall management strategy, and finally, study designs differ. Nevertheless, most studies report that renal transplantation is the least expensive treatment modality [4, 23, 24] , as we found. Nonetheless, the additional costs of organ procurement and the first months after transplantation must be considered in evaluating the global cost of transplantation. As Barnieh et al. reported [34] , we showed here and in a previous study [38] that costs associated with pretransplantation stages varied from 19,618 € for a deceased donor to 12,241 € for a living donor. The mean costs after transplantation start at 26,155 € for the month immediately following the graft and decrease rapidly, but the monthly cost is still 2821 € after 6 months. These results demonstrate the importance of a dynamic view of renal care and the bias likely when comparing treatments in cross-sectional studies.
Three reviews have concluded that PD in Western countries tends to be less expensive than HD [24, 27, 41, 42] . Our study, by taking into account the dialysis technique but also the site and medical environment allows us to moderate the results of these reviews. The mean monthly cost runs along a continuum from 3774 € for non-assisted CADP patients to 7253 € for patients on hemodialysis in a hospital-based in-center unit. The latter's highest monthly mean cost is due to the direct cost of the dialysis session and the transport. Nurse-assisted PD patients had the second highest cost, despite the lower direct cost of the technique, especially for CAPD, and the very low transportation costs for PD patients treated at home. The nursing assistance result is principally responsible for this result (nurses' fees average 1500-2000 € monthly), together with their hospitalization rates, higher than those of patients in medical outcenter satellite units. Non-assisted automated PD and HD in self-care or nurse-assisted satellite units have similar mean monthly costs, because the actual dialysis costs are equivalent and the transportation for HD and the hospitalization and personal autonomy allowances for APD balance each other out. Patients treated by home HD have higher monthly costs due to the direct cost of dialysis and pharmaceutical expenditures than non-assisted CAPD patients do, although the latter have higher costs related to hospitalization.
Because we stratified our analysis according to age and diabetes status, we were able to show that for each separate A comprehensive approach to assess the costs of renal replacement therapy for end-stage… 467 modality, patients with diabetes, especially young ones, had higher mean monthly costs than patients without diabetes treated by the same modality. A German study found that age was associated with dialysis-related costs, but diabetes and ESRD duration were not [13] . The less obvious effect of age on monthly cost for each modality in our study may be due to the strong association between the eight available dialysis modalities and the case mix. Young incident patients have a higher first-month cost, especially when starting with PD. This might be explained by their longer hospitalization, until they can perform PD autonomously, but also to the cost of the clinical evaluation before placement on the renal graft waiting list.
As in other studies, mean costs for patients who died at a young age were higher than for people whose deaths took place when they were older [43] , due mainly to the higher costs for their hospitalization (excluding RRT fees).
The major strengths of this analysis include the unselected nature of the population (exhaustive nationwide database) in comparison with other studies and the in-depth analysis of the factors associated with the variations of the costs, like patient characteristics and transitions costs. In addition to mean monthly cost for prevalent stable patients (same treatment over 9 months), we also calculated the additional costs for clinical events and transitions, including dialysis start, renal transplantation, death, and changes between dialysis modalities; all those clearly affect total lifetime costs. Some strategies, such as renal transplantation or home hemodialysis, may be less expensive as a stable monthly RRT but may have high transition costs. Thus, as an example, the cost of renal transplantation, including the donor-related costs and the first 6 months (total 70,739 € for a deceased donor) is equivalent to 10 months HD in a hospital-based in-center unit, 16 months HD in a self-care or nurse-assisted satellite unit or non-assisted APD, or 18 months of non-assisted CAPD.
This study has some limitations. First, the data available did not allow us to estimate the monthly cost for a prevalent patient according to the time since its first treatment. We hypothesize that this cost is stable over life-time, except in the case of events such as renal transplantation, death, or transfer to an autonomous modality. Second, the costs paid by patients and carers were not taken into account because they were not available in the French administrative databases of the French national health insurance information system we used. Third, costs identified were aggregated reimbursed expenses by French national health insurance and therefore the reporting of quantities of resource and unit costs was not possible. Fourth, in our study we estimated the global cost of care for ESRD patients, including costs linked to comorbidities or complications. Therefore, the transposability in other countries with quite different case mixes and management strategies may be debated. Finally, more in-depth studies on the associations between transition costs and medical or non-medical factors were not possible [34, 44, 45] .
In conclusion, this study confirms the importance of an in-depth analysis of the different costs for ESRD patients and their factors of variations like the specific available treatment modalities (ten in France), the patients' characteristics (age and diabetes status), and clinical events over the study period (dialysis start, transfer to an autonomous modality, renal transplantation or death). Although the costs estimated here are clearly related to French reimbursement levels, this study shows in detail the various factors of variation and the details of the cost headings. It may therefore help other countries to evaluate and anticipate future strategies of renal care.
